Sanofi in the News: Grand Expectations and Paul Hudson's $12.3M Salary

It’s been a busy week for Sanofi. On March 29, the company inked a pact with IGM Biosciences that could surpass $6 billion. The two companies will collaborate on treatments for oncology, immunology and inflammation. IGM Biosciences focuses on engineered IgM antibodies with more binding sites than conventional IgG antibodies. They will focus on three cancer targets and three immunology/inflammation targets, with each target having a range of developmental and regulatory milestones and royalty splits.